Trial Profile
A multi-Center Randomized, Double-Blind, Placebo-Controlled Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction and Maintenance of Clinical Remission in Subjects With Crohn's Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Mar 2018
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Crohn's disease
- Focus Pharmacodynamics; Therapeutic Use
- Acronyms ADHERE; CHARM
- Sponsors Abbott Laboratories
- 07 Mar 2018 Results of pooled data from 11 induction, maintenance and open-label extension studies of adalimumab, were published in the Advances in Therapy.
- 27 Jan 2018 Results assessing the safety of Adalimumab Dosed Every Week and Every Other Week in patients from this and 12 other studies, published in the American Journal of Clinical Dermatology
- 07 Nov 2016 Results of post hoc analysis of this and other five studies (CLASSIC-I, GAIN, CHARM, EXTEND, ULTRA 1 AND ULTRA 2) published in the Alimentary Pharmacology and Therapeutics